Claims
- 1. An immunophilin, comprising a protein with the following properties:
(i) a protein of 8.4 kDa mass; (ii) isolated from the soluble cytoplasm of lymphoid tissues; (iii) the N-terminal first 23 amino acid sequence is: 2MET GLN ILE PHE VAL LYS THR LEU THRSeq. ID No. 1GLY LYS THR ILE THR LEU GLU VAL GLUPRO SER ASP THR ILEand, (iv) capable of specifically binding FK-506, rapamycin, or pharmacologically active metabolites or derivatives thereof, but not cyclosporins.
- 2. An immunophilin according to claim 1, wherein said protein exhibits retention times on HPLC identical to that of authentic ubiquitin.
- 3. An immunophilin according to claim 1, wherein said protein migrates on SDS-PAGE electrophoresis plates identically to authentic ubiquitin.
- 4. An immunophilin according to claim 1, wherein said protein exhibits a Kd of about 0.8 nM for FK-506 and 0.08 nM for rapamycin.
- 5. An immunophilin according to claim 1, wherein said protein has a Hill plot value of about unity.
- 6. An immunophilin according to claim 1, wherein said protein, and when complexed to FK-506, inhibits calcineurin phosphatase activity.
- 7. A recombinant 8.4 kDa immunophilin with the properties exhibited by the immunophilin according to claim 1.
- 8. A mercantile kit for the determination of immunosuppressant drugs FK-506, rapamycin and pharmacologically active metabolites and derivatives thereof in a fluid sample, comprising, in separate compartments: said isolated 8.4 kDa immunophilin; optionally, one or more of unlabeled said immunosuppressant drugs or pharmacologically-active metabolites or derivatives thereof; and, optionally, one or more labeled said immunosuppressant drugs or pharmacologically-active metabolites or derivatives thereof.
Parent Case Info
[0001] This is a divisional application of pending U.S. Ser. No. 09/643,723, filed Aug. 23, 2000.
Divisions (1)
|
Number |
Date |
Country |
Parent |
09643723 |
Aug 2000 |
US |
Child |
10073334 |
Feb 2002 |
US |